Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02JEW
|
|||
| Former ID |
DIB015410
|
|||
| Drug Name |
GSK-2130579A
|
|||
| Synonyms |
Leukemia vaccine, GlaxoSmithKline; WT1 ASCI, GlaxoSmithKline; WT1 antigen specific cancer immunotherapeutic, GlaxoSmithKline; WT1 vaccine, GlaxoSmithKline
Click to Show/Hide
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 1 | [1] | |
| Company |
Glaxosmithkline
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Wilms tumor protein (WT1) | Target Info | . | [2] |
| KEGG Pathway | Transcriptional misregulation in cancer | |||
| NetPath Pathway | FSH Signaling Pathway | |||
| IL5 Signaling Pathway | ||||
| Pathway Interaction Database | p73 transcription factor network | |||
| Regulation of Telomerase | ||||
| WikiPathways | Primary Focal Segmental Glomerulosclerosis FSGS | |||
| Integrated Pancreatic Cancer Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01051063) Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy. U.S. National Institutes of Health. | |||
| REF 2 | Spoilight on personalized medicine. A pharma matters report, Thomson Reuters, 2012. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.